MannKind Presents Poster at 15th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD 2022) to Be Held April 27-30
April 27 2022 - 06:05AM
MannKind Corporation (Nasdaq: MNKD), a company
focused on the development and commercialization of inhaled
therapeutic products for patients with endocrine and orphan lung
diseases, announced today that it has presented a poster [Abstract
#445] at the 15th International Conference on Advanced Technologies
& Treatments for Diabetes (ATTD 2022) held April 27-30 in
Barcelona and virtually. The poster is now available to meeting
attendees online.
The proof-of-concept study demonstrated that a simplified 2x
dose of Technosphere® Insulin (TI) provided significant reductions
in post-prandial glucose excursions (PPGE) versus the current label
dosage guidelines, with no new safety concerns. PPGE was tracked
from 0 to 120 minutes following a standardized meal that was
preceded by a dose of TI calculated in one of two ways: either
based on the guidelines set forth in the current Afrezza® packaging
(Dose 1) or by doubling the subject’s injectable insulin dose and
rounding down to the nearest available TI dose (Dose 2). A
statistically significant improvement in PPGE was observed between
Dose 1 and Dose 2 from 45-120 minutes, and the higher dose of TI
resulted in a mean difference of 52 mg/dL at 120 minutes.
“We continue to explore new ways to help patients living with
diabetes achieve better glycemic control and address potential
underdosing with this therapy,” said Dr. Kevin Kaiserman, Vice
President, Medical Affairs & Safety, Endocrine Business Unit
for MannKind. “The DOS study provides valuable insights to inform
our titration approach as we look at our current studies, including
the INHALE-1 study of Afrezza in the pediatric population.”
“The perceived effect of the first dose of a medication greatly
impacts the likelihood of a person taking a second dose of that
medication,” said Dr. Timothy S. Bailey, MD, FACE, CPI, CEO &
Founder of AMCR Institute. “This study demonstrated that using
twice the previously recommended starting dose was more effective
at managing post-prandial glucose excursions with no new safety
concerns. Recommending this optimized dosing to people with
diabetes has the potential to improve their post-prandial glucose
control and persistence with this medication.”
Twenty adult participants (≥ 18 years) with type 1 diabetes
(T1D) or type 2 diabetes (T2D) who were on subcutaneous basal-bolus
insulin therapy were enrolled in the DOS study. On the first study
visit, each subject received a standard meal that was preceded by
Dose 1 of TI. At the next visit (2-3 days later), each subject
received an identical meal that was preceded by Dose 2 of TI.
Capillary blood glucose (SMBG) was measured immediately prior to
the dose of TI and then afterward at 15, 30, 45, 60, 90 and 120
minutes.
The poster was authored by Timothy S. Bailey, MD; Mark
Christiansen, MD; Sunil Bhavsar; Johanna Ulloa; Brandi Santogatta;
Joseph Hanna; and Kevin Kaiserman, MD – representing a
collaboration between the AMCR Institute (Escondido, Calif.),
Diablo Clinical Research (Walnut Creek, Calif.), and
MannKind. About MannKind
CorporationMannKind Corporation (Nasdaq: MNKD) focuses on
the development and commercialization of inhaled therapeutic
products for patients with endocrine and orphan lung diseases.
MannKind is currently commercializing Afrezza® (insulin human)
Inhalation Powder, the Company’s first FDA-approved product and the
only inhaled ultra rapid-acting mealtime insulin in the United
States, where it is available by prescription from pharmacies
nationwide. Afrezza is also available by prescription in Brazil,
where it is commercialized by the Company’s partner, Biomm SA.
MannKind was established in 1991, and is located in Danbury, Conn.,
and Westlake Village, Calif. The Company also employs field sales
and medical representatives across the U.S. Please visit
mannkindcorp.com to learn more.
Forward-looking StatementsThis press release
contains forward-looking statements about future clinical studies
and the implications of clinical data that involve risks and
uncertainties. Words such as “believes”, “anticipates”, “plans”,
“expects”, “intends”, “will”, “goal”, “potential” and similar
expressions are intended to identify forward-looking statements.
These forward-looking statements are based upon MannKind’s current
expectations. Actual results and the timing of events could differ
materially from those anticipated in such forward-looking
statements as a result of various risks and uncertainties, which
include, without limitation, the risk that continued testing of
Afrezza may not yield successful results or results that are
consistent with earlier testing, and other risks detailed in
MannKind’s filings with the Securities and Exchange
Commission, including its Annual Report on Form 10-K for the year
ended December 31, 2021 and subsequent periodic
reports on Form 10-Q and current reports on Form 8-K. You are
cautioned not to place undue reliance on these forward-looking
statements, which speak only as of the date of this press release.
All forward-looking statements are qualified in their entirety by
this cautionary statement, and MannKind undertakes no
obligation to revise or update any forward-looking statements to
reflect events or circumstances after the date of this press
release.
TECHNOSPHERE and AFREZZA are registered trademarks of MannKind
Corporation.
MANNKIND CONTACTS:
Christie Iacangelo, Corporate Communications
(818) 292-3500
Email: media@mannkindcorp.com
Rose Alinaya, Investor Relations
(818) 661-5000
Email: ir@mannkindcorp.com
MannKind (NASDAQ:MNKD)
Historical Stock Chart
From Feb 2024 to Mar 2024
MannKind (NASDAQ:MNKD)
Historical Stock Chart
From Mar 2023 to Mar 2024